Clinical Trial

SMART 2D: Study of Montelukast's Effects on Renal and Cardiovascular Health in Adolescents and Young Adults With Type 2 Diabetes

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
Adolescents and young adults (AYA) with type 2 diabetes (T2D) have a more severe phenotype than what is seen in youth-onset type 1 diabetes or adult-onset T2D including earlier kidney and cardiovascular disease complications; and prioritizing new treatments, either for standalone use or in combination with other therapies is critical. T2D triggers the release of proinflammatory mediators called cysteinyl leukotrienes leading to damage to the kidneys and blood vessels. This clinical trial will evaluate the effects of montelukast, a cysteinyl leukotriene inhibitor, on kidney and vascular function in AYA with T2D to help direct future diabetes care to limit diabetic kidney and cardiovascular disease complications.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-12.
Trial Details
NCT Number NCT07409714
Lead Sponsor University of Colorado, Denver
Conditions Type 2 Diabetes
Enrollment 50 participants
Start Date 2026-07
Primary Completion 2030-02 (estimated)
Study Completion 2030-02 (estimated)
Updated on ClinicalTrials.gov 2026-05-14